## BeOne Secures China Approval for Amgen's Breakthrough Lung Cancer Drug Imdelltra
BeOne has secured a critical regulatory win in China, gaining approval to commercialize Amgen's innovative lung cancer therapy, Imdelltra. This move grants the Chinese biotech firm exclusive rights to market the drug in one of the world's largest oncology markets, marking a significant milestone for both companies. The approval positions Imdelltra as a new treatment option for patients with extensive-stage small cell lung cancer (ES-SCLC), a particularly aggressive form of the disease with historically limited effective therapies.

The approval follows a strategic licensing agreement between Amgen and BeOne, which was established to accelerate the drug's entry into the Chinese market. Imdelltra, known generically as tarlatamab, is a bispecific T-cell engager (BiTE) immunotherapy that represents a novel mechanism of action. Its clearance by China's National Medical Products Administration (NMPA) is based on robust clinical trial data demonstrating its efficacy in patients whose cancer has progressed after platinum-based chemotherapy.

This development intensifies competition within China's rapidly growing oncology drug market, where both domestic and international pharmaceutical companies are vying for share. For Amgen, the partnership with a local player like BeOne is a key strategic move to navigate China's complex regulatory and commercial landscape efficiently. For Chinese patients with ES-SCLC, the availability of Imdelltra introduces a potentially practice-changing treatment, addressing a major unmet medical need and signaling a shift towards more advanced, targeted immunotherapies becoming accessible locally.
---
- **Source**: Seeking Alpha
- **Sector**: The Lab
- **Tags**: pharmaceuticals, oncology, regulatory approval, China market, biotech partnership
- **Credibility**: unverified
- **Published**: 2026-04-10 17:52:21
- **ID**: 59314
- **URL**: https://whisperx.ai/en/intel/59314